Logo

Bioline EPIK miRNA Select Kits

Mar 03, 2016

Bioline, a Meridian Bioscience company, has launched its EPIK miRNA Select assays worldwide. These assays were developed to study individual microRNA (miRNA) molecules. The individual assays use the same approach developed by MiRXES for the EPIK miRNA Panel assays; they employs miRNA-specific reverse transcriptase primers and hemi-nested real-time PCR primers along with Bioline reverse transcriptase, SensiSMART with SYBR Green, and highly optimized buffers. This combination of technology enables the assays to detect extremely low levels of miRNA with very high specificity, which makes it possible to discriminate between closely related miRNA sequences, the company said.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.